Brief: Janux Therapeutics Anticipates Providing An Update On Doses For Expansion In Second Half Of 2024

Janux Therapeutics

26/02/2024 22:07

Feb 26 (Reuters) - Janux Therapeutics Inc  JANX.O :
    * JANUX ANNOUNCES ENCOURAGING SAFETY AND EFFICACY DATA IN
ONGOING
DOSE ESCALATION TRIALS FOR PSMAXCD3-TRACTR JANX007 IN MCRPC AND
EGFRXCD3-TRACTR JANX008 IN SOLID TUMORS
    * JANUX THERAPEUTICS INC - 83% (5/6) OF SUBJECTS ACHIEVED
PSA(50
)DECLINES WITH FIRST STEP DOSE ≥ 0.2MG
    * JANUX THERAPEUTICS INC - 56% (10/18) OF SUBJECTS ACHIEVED
PSA(50
)DECLINES WITH FIRST DOSE ≥ 0.1MG
    * JANUX THERAPEUTICS INC - NO CRS GREATER THAN GRADE 2 WAS
OBSERVED IN ANY COHORT
    * JANUX THERAPEUTICS INC - NO CRS GREATER THAN GRADE 1
OBSERVED IN
ANY COHORT
    * JANUX THERAPEUTICS INC - NO TREATMENT RELATED SAES OR DLTS
HAVE
BEEN OBSERVED
    * JANUX THERAPEUTICS INC - ANTICIPATES PROVIDING AN UPDATE
ON
DOSES FOR EXPANSION IN SECOND HALF OF 2024

Source text for Eikon:  ID:nBw3cKVgGa 
Further company coverage:  JANX.O 

 ((reuters.briefs@thomsonreuters.com;))